Purpose: To compare the extent of enhancement of abdominal organs as shown on subphases of hepatic arterial phase quantitatively between 1.5- and 3.0-T MRI among patients with various abdominal conditions.
Materials And Methods: A total of 126 patients, of whom 68 were women (age range, 3-82 years; mean age, 48 years) and 58 were men (age range, 6-73 years; mean age, 50 years), were included in the study. Of 126 patients, 98 were scanned at 1.5 T and 28 were scanned at 3.0 T. The presence of one of three predefined subphases of hepatic arterial phase was determined on early post-gadolinium sequence in each patient by two reviewers in consensus. Extent of enhancement of the kidney, pancreas, spleen and liver on these subphases was determined quantitatively by measuring the signal intensities. Mann Whitney-Wilcoxon test was used to compare the contrast enhancement of organs on each subphase between 1.5- and 3.0-T MRI.
Results: The kidney, spleen, pancreas and liver demonstrated 1.79- to 2.45-, 1.65- to 1.97-, 1.66- to 1.8- and 1.1- to 2.02-fold higher enhancement on the subphases of hepatic arterial phase at 3.0 T compared to 1.5 T, respectively. The differences in contrast enhancement were significant for the kidney, pancreas and spleen on all subphases between 1.5 and 3.0 T.
Conclusion: The relative enhancement of the kidney, spleen and pancreas is consistently and significantly higher at 3.0 T than at 1.5 T in matched subphases of hepatic arterial enhancement.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.mri.2009.05.041 | DOI Listing |
Pediatr Radiol
January 2025
Diagnostic and Interventional Radiology Department, Hospital for Sick Children, 555 University Ave, Toronto M5G 1X8, Toronto, Canada.
Background: Hepatocellular adenomas (HCAs) are rare, benign hepatic tumors in children, with limited imaging data available for pediatric cases.
Objective: To describe the magnetic resonance imaging (MRI) and clinical features of histologically proven HCAs in children.
Materials And Methods: Single-center retrospective review of pathology-proven HCA from January 2004 to February 2024.
Sci Rep
January 2025
General and Digestive Unit, Central Hospital of Defense, Spanish-Ministry of Defense, Glorieta del Ejército, 1, 28047, Madrid, Spain.
This study aims to evaluate two of the most commonly used products, the collagen-based patch (Hemopatch) and the micropolysaccharide microspheres powder (Perclot), in the context of stab liver injury in pigs. The objectives of this study were to assess blood loss at various time intervals up to 24 h, survival rates, and mean arterial pressure. The research involved 18 Large-White swine.
View Article and Find Full Text PDFJ Biomater Appl
January 2025
The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and remains a fatal malignancy in most patients. Only 20% to 30% of patients can be treated with potentially curative surgical resection. Local therapies such as radioembolization and hepatic arterial perfusion may be a more effective treatment strategy.
View Article and Find Full Text PDFACS Appl Mater Interfaces
January 2025
Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing, Jiangsu 210094, China.
Uncontrolled bleeding and infection following trauma continue to pose significant clinical challenges. This study employs hemoadhican (HD) polysaccharide, known for its superior hemostatic properties, as the foundational material to synthesize antibacterial carbon dots (H-CDs) through a hydrothermal method at various temperatures. The H-CDs exhibiting optimal antimicrobial properties were identified via in vitro antimicrobial characterization.
View Article and Find Full Text PDFImmunotargets Ther
January 2025
Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Purpose: To compare the clinical outcomes of different systemic therapies, specifically PD(L)1 inhibitors plus Lenvatinib versus Atezolizumab plus Bevacizumab, when combined with hepatic arterial infusion chemotherapy (HAIC) based on the FOLFOX regimen (oxaliplatin, fluorouracil, and leucovorin) as first line treatment for unresectable hepatocellular carcinoma.
Patients And Methods: This real-world retrospective study enrolled 294 patients with unresectable HCC. All patients received HAIC in combination with either PD(L)1 inhibitors plus Lenvatinib (PLEN-HAIC) or Atezolizumab plus Bevacizumab (AT-HAIC).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!